Press Releases April 23, 2026 04:30 PM

AerSale® Announces Date for First Quarter 2026 Earnings Release Conference Call

AerSale schedules Q1 2026 earnings release and conference call on May 7, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
ASLE

AerSale Corporation announced it will release its first quarter 2026 earnings results after market close on May 7, 2026, followed by a conference call to discuss the results. The company is a comprehensive provider of aviation aftermarket services including sales, leasing, maintenance, and engineered solutions for commercial aircraft.

AerSale® Announces Date for First Quarter 2026 Earnings Release Conference Call
ASLE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 earnings release scheduled for May 7, 2026.
  • Conference call and live webcast planned to discuss financial results.
  • AerSale offers integrated aviation aftermarket services supporting Boeing, Airbus, and McDonnell Douglas aircraft operators, impacting aerospace and aviation service sectors.

MIAMI, April 23, 2026 (GLOBE NEWSWIRE) -- AerSale Corporation (NASDAQ: ASLE) (the “Company”), announced today that it will release its earnings results for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, after the market closes. The Company will host a conference call on the same day at 4:30 pm Eastern Time to discuss the results.

A live audio webcast of the call will be available to the public on a listen‑only basis at https://ir.aersale.com/news-events/events. An archived replay of the webcast will also be available on the Investors portion of the AerSale website at https://ir.aersale.com for one year.

About AerSale

AerSale is a global provider of integrated aviation aftermarket services and solutions, serving operators of Boeing, Airbus, and legacy McDonnell Douglas aircraft. The Company helps aircraft owners and operators optimize the value, safety, and operational efficiency of their fleets across the entire aircraft lifecycle.

AerSale’s comprehensive capabilities include aircraft and engine sales and leasing, used serviceable material (USM) sales, component and airframe MRO services, and FAA-certified engineered solutions. Through internally developed products such as AerSafe®, AerTrak®, and the AerAware™ Enhanced Flight Vision System, AerSale delivers innovative technologies that enhance aircraft performance, improve safety, and reduce operating costs.

With deep technical expertise and a fully integrated business model, AerSale provides everything customers need—through a single, trusted partner.

Media:
For more information about AerSale, please visit our website:www.AerSale.com.
Follow us on: LinkedIn | Twitter | Facebook | Instagram

AerSale: Jackie Carlon
Telephone: (305) 764-3200
Email: media.relations@aersale.com

Investor:
AerSale: InvestorRelations@aersale.com

Source: AerSale Corporation


Risks

  • Earnings performance may be affected by fluctuating demand in the aerospace aftermarket sector, impacting revenue and profitability.
  • Potential operational risks associated with maintaining regulatory certifications (FAA) and delivering engineered aviation solutions.
  • Market conditions affecting aircraft sales, leasing, and maintenance services could introduce uncertainties in future financial results.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026